NewYorkBIO Board of Directors
Judith Dunn, PhD
Chairman of the Board
Judy Dunn is Vice President, Global Head of Clinical Development and Head, Innovation Center at Roche. Judy also leads the Roche Innovation Center in New York located in the Alexandria Center for Life Science in Manhattan. Prior to joining Roche, Judy held positions in both the research and commercial divisions of Pfizer, led clinical programs in psychiatry at Sepracor, and served as Vice President of Clinical Research at Flexion, a start-up biotech company.
In addition, she is a founding member and Chair of the Scientific Program Committee for the CNS Summit, an organization focused on delivering new treatments to patients suffering from brain disorders through stakeholder collaboration.
Judy attended Wesleyan University and the University of Rochester, where she obtained undergraduate and graduate degrees in Neurobiology. She has been the recipient of a research fellowship in neuropharmacology from the Center for Brain Research at Strong Memorial Hospital and a Postdoctoral Fellowship in Clinical Research from Pfizer.
Immediate Past Chairman
Bob Easton is Co-Chairman of BioNest Partners, an international consulting firm. For over 25 years, Bob Easton has been recognized as a leader in healthcare business consulting. He has built and led two top firms, beginning with the founding of The Wilkerson Group in 1985. He has led scores of market development and strategic advisory assignments for clients, including large and specialty pharmaceutical companies, early-stage through publicly traded biopharmaceutical companies, and diagnostics businesses. He has influenced the decision-making of numerous healthcare professionals and supported hundreds of clients executives in Australia, Japan, Canada, U.S., Europe and Israel. His interest in healthcare began when he managed a medical diagnostics business for Union Carbide.
Peter Robinson, MPH
Peter Robinson is the Vice President and Chief Operating Officer of the University of Rochester Medical Center. In January 2004, Mr. Robinson was appointed to the additional responsibility of Executive Director of Government and Community Relations for the University. He also has responsibility for the University’s role in economic development.Mr. Robinson is a voting member of the New York State Public Health Council, the Chairman of the Board of High Technology of Rochester, Inc. (HTR), and of Excell Partners, Inc. and serves on the boards of several private and public community agenciesHe earned his bachelor’s degree from the City College of New York and Master’s degrees from the New School for Social Research and Columbia University.
Robert Van Nostrand
Executive Committee, Treasurer
Bob Van Nostrand has been associated with NewYorkBIO for more than two decades. He was CFO of OSI Pharmaceuticals for over 20 years, helping to grow the company from an early phase to a major acquisition target. He has also been CFO of Aureon and is a member of the Board of Directors of Achillion.
Cynthia Green, PhD, MBA
Executive Committee, Secretary
Cyndi Green is a Senior Director in Worldwide Business Development at Pfizer with responsibility for anti-infectives and vaccines. Cyndi joined Pfizer NYHQ in 2003 as Associate Director of Operations in Licensing and Development and has broad biotech and pharma experience in business development, strategy, venture capital and consulting. Currently, Cyndi has responsibility for partnering marketed and clinical stage assets, technologies, diagnostics, research platforms and patents. Cyndi played an integral role in the formation of RGo Biosciences (previously a resident in The Pfizer Incubator), led diligence activities for the formation of the Pfizer-GSK HIV joint venture (ViiV Healthcare), and has led/co-led a multitude of licensing assessments and divestitures over the years.
Executive Committee, At-Large
Ms. Jane Wasman, J.D., is President International, General Counsel, Corporate Secretary of Acorda Therapeutics, Inc. She was appointed as President International of the Company on October 9, 2012. She served as Chief Strategic Development of the Company. From May 2004 until January 2012, she was the company Executive Vice President, General Counsel and Corporate Secretary. From 1995 to 2004, Ms. Wasman held various leadership positions at Schering-Plough, including Staff Vice President and Associate General Counsel responsible for legal support for U.S. Pharmaceuticals operations, including sales, marketing and compliance; FDA regulatory matters; global research and development; and corporate licensing and business development. Ms. Wasman is also Chairperson of the Public Policy Committee.
Donald Mazzullo, Esq.
Executive Committee, General and Legislative Counsel
Mr. Mazzullo is Partner at Harter Secrest and Emory and has represented a wide range of companies, not-for-profits, and associations in the state capital for twenty-three years. He started the government affairs practice group at Harter Secrest & Emery in 1984, and under his leadership, it has become an effective and respected lobbying firm. During that time, he has developed relationships with legislators on both sides of the aisle, has worked with several administrations, and has navigated numerous leadership changes in the Legislature.Mr. Mazzullo has represented a variety of clients in many industry sectors, including the New York State Restaurant Association, New York Biotechnology Association, GlaxoSmithKline, Delta Air Lines, Emerging Industries Alliance of New York State, New York State Chiropractic Association, Association of Safety Group Managers, Genesee & Wyoming Railroad, Amalgamated Transit Union, New York State Telecommunications Association, DaimlerChrysler Corporation, Cold Spring Harbor Laboratory, Genencor (A Danisco Company), OSI Pharmaceuticals, New York Hall of Science, and New York State Clinical Laboratory Association, together with numerous other private corporations and municipal, civic, and charitable organizations.
Dan is Managing Director, Senior Vice President, Life Science and Technology Practice Leader at Conner Strong and Buckelew where he is responsible for all aspects of risk management & insurance products and services delivered to Life Science & Technology clients of Conner Strong & Buckelew. In addition, he has management responsibilities for growing the practice within the strategic plan of the overall insurance brokerage. Brettler has 20 years of solid risk management & insurance experience, the majority of which has been devoted exclusively to the Life Science & Technology industries. Specific areas of insurance expertise include on a global basis Products Liability, Human Clinical Trials, Directors’ & Officers’ Liability and Property Coverage for GMP facilities.
Rich Catalano is an Audit Partner at KPMG and has over 30 years of experience in life science.
Ellen Corenswet, Esq.
Ellen Corenswet is co-chair of Covington & Burling’s Venture Capital/Emerging Company Practice Group and a member of its Life Sciences Practice Group, resident in the New York office. She represents private and public companies, principally in the life sciences, media/social media, software, Internet and technology industries. She also represents venture capital firms and corporate venture groups in their investments in these companies. Ms. Corenswet typically acts as outside general counsel to company clients. She advises early stage companies on structuring issues, founders’ equity, compensation and equity plans, intellectual property issues, and early stage equity and convertible debt financings. She advises later stage companies on venture capital financings and private placements, corporate governance, equity incentives, IPOs and follow-on public and private offerings, SEC disclosure and compliance, and M&A transactions. Ms. Corenswet has practiced law in Northern California, Boston and New York and brings together a broad perspective and network from these three communities.
Ed Haug is a founding partner of Frommer Lawrence & Haug LLP, where he has served as Managing Partner since 2005. Mr. Haug is a nationally recognized intellectual property trial lawyer and consultant specializing in protecting his clients’ intellectual assets in complex technical fields, including pharmaceuticals and biotechnology. He ensures that clients such as Shire Pharmaceuticals and The Medicines Company obtain full patent protection for their life science innovations while complying with all regulations, and, if needed, he defends their intellectual property from infringement. Mr. Haug has extensive experience both trying cases to courts and juries and arguing appeals in the United States, including before the U.S. Supreme Court. He has also defended cases in the United Kingdom, Germany, and Japan. He also regularly counsels clients in due diligence investigations. Currently, Mr. Haug serves as the Immediate Past President of the Federal Circuit Bar Association, a national bar association that represents approximately 3,000 lawyers, judges, and academics, that helps shape national legislation affecting intellectual property. In addition, Mr. Haug is a prolific lecturer, frequently sharing his knowledge about trial advocacy in patent litigation around the world.
Todd Little is President Translational Models and Solutions and Product Development at Taconic. A Taconic employee since 1991 and CEO since 2009, Little has 30 years of experience in the development and production of in vivo models and services for drug discovery and pre-clinical investigations. Prior to Taconic he was Director of Sales and Marketing at Verax and National Sales Manager for Charles River Laboratories. During his tenure at Taconic, he spearheaded Taconic’s initial diversification into technical services (e.g. monoclonal antibody production and genotyping assays) and, as Vice President of Operations, led the construction and startup of the company’s newest and most technologically advanced breeding facilities in Cambridge City, IN and Albany, NY. Little has been responsible for leading the day-to-day operations of the company as President since February 2007. His appointment as CEO 2009 marked the first time in the 50+-year history of the family-owned company that a non-family member has held the CEO position.
Joel S. Marcus is the Chairman, Chief Executive Officer, and Founder of Alexandria Real Estate Equities, Inc./ Alexandria Venture Investments (NYSE:ARE), an urban office REIT uniquely focused on collaborative life science and technology campuses in AAA innovation cluster locations. Mr. Marcus co-founded Alexandria in 1994 as a garage startup with $19 million in seed capital and has led its growth into an S&P 500 company with an approximately $16 billion total market capitalization and a total shareholder return of more than 1,200% since the company’s IPO in 1997. Today, Alexandria, which celebrated its 20th anniversary as an NYSE listed REIT in May 2017, is the only publicly traded pure-play office/laboratory REIT.
Hala Mirza is Vice President, Corporate Communications, at Regeneron.
Timothy O'Connor, PhD
Timothy O’Connor was appointed executive vice president of The Rockefeller University in February 2016. In this role, he oversees most university operations, including research support, technology transfer, facilities, and information technology, as well as finance, investments, human resources, and legal affairs. Working in partnership with the other executive officers, he provides administrative leadership to the university and represents the president both internally and externally. He originally joined the university in 2013 as chief of staff and vice president. Dr. O’Connor’s career has focused on both biomedical research and academic administration. Most recently, he served as associate provost for science and technology at Yale University; prior to that, he was associate research professor and vice chair in the Department of Genetic Medicine at Weill Cornell Medical College. He currently serves on the boards of the New York Structural Biology Center, the Aaron Diamond AIDS Research Center, and Accelerator Corporation, a biotechnology investment and management company.
Joel Papernik is partner at Mintz Levin. Joel concentrates on corporate, commercial, and securities matters as well as strategic transactions and corporate structuring. He is a member of the firm’s Opinions Committee and has also served as a member of the firm's Policy Committee.He has extensive experience counseling high-technology businesses and the individuals creating them. He frequently guides acquisitions, collaborations, and licensing transactions in the life sciences industry. As more life sciences companies have extended their activities from discovery to development, his practice has been more involved with development and later stage activity.
Greg Plowman, PhD
Dr. Plowman holds a Joint appointment as Vice President Oncology Research at Eli Lilly and Senior Vice President, Research at ImClone. He previously served as a senior director in research for six years at Genentech, a member of the Roche Group. He directed research efforts in anti-angiogenesis (attempting to block the formation of blood vessels that supply nutrients and oxygen that encourage cancerous tumor growth), biomedical imaging, and tumor biology and was responsible for building a pipeline of innovative agents for treatment of cancer and ocular disease.He has 25 years of experience in cancer research including leadership roles at four biotechs (Oncogen, Sugen, Exelixis, and Genentech) that became part of three pharmaceutical companies (Bristol-Myers Squibb, Pharmacia, and Roche).
Prem Premsrirut, PhD
Dr. Premsrirut is CEO of Mirimus and an expert in the development and use of RNAi transgenic mice. She was an inventor of technological advancements that lead to the development of a high-throughput platform for rapid and efficient generation of conditional RNAi transgenic mice. She pioneered a novel approach for the generation of "speedy” chimeric GEMMs based on rederivation of mouse embryonic stem cells (ESCs) from existing mouse strains with a predisposition to cancer. Dr. Premsrirut received a Ph.D. in genetics following her training in the laboratory of Dr. Scott Lowe at Cold Spring Harbor Laboratory.
Mr. Purcell is the original Founder of Aisling Capital LLC and currently serves as a Senior Advisor to Aisling. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, "H&Q”) for over five years. While at H&Q, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.
Lily Safani is CEO of Gilda’s Club NYC.
Sapan Shah, PhD
Dr. Shah is Founder and CEO of Novatherx, providing expertise, leadership and support to biotech and pharmaceutical companies advancing innovative therapeutics that address areas of critical unmet medical need. He was previously President and Chief Executive Officer of ARMGO Pharma, a biotechnology company developing novel small-molecule therapeutics to treat debilitating cardiac and rare muscle diseases. Prior to ARMGO, Dr. Shah served as President and CEO of Shionogi Inc., and during that time launched and expanded the US pharmaceutical business of Shionogi & Co., Ltd., established and operated a joint-venture with GSK/ViiV focused on development and commercialization of a novel HIV integrase inhibitors, and co-founded Ezose Sciences, a high-throughput glycomics company. He began his career at McKinsey & Company, advising pharmaceutical and biotech clients on a wide range of R&D, commercial and corporate strategy matters. Dr. Shah earned his Ph.D. degree in Molecular Biophysics and Biochemistry from Yale University and holds BA degrees in Mathematics and Biochemistry from the Integrated Science Program at Northwestern University.
Arthur Tinkelenberg, PhD
Dr. Arthur H. Tinkelenberg, PhD is former President and Chief Executive Officer of Enumeral Biomedical Corporation. Dr. Tinkelenberg previously served as a Partner of Ascent BioMedical Ventures (ABV). Prior to joining ABV, Dr. Tinkelenberg worked in the Healthcare Investment Banking and Mergers and Acquisitions Groups at Robertson Stephens, where he advised clients on strategic and financing alternatives and participated in over $250 million in public, private, and merger transactions for biotechnology, medical device, and diagnostics companies. He served as a Director of Xlumena Inc. Dr. Tinkelenberg earned his Ph.D. degree in Molecular Genetics from The Rockefeller University where he studied cell growth regulation and signal transduction as a Rockefeller and National Science Foundation Fellow and earned his BA degree in Biology, with honors, from Grinnell College.
Robert G. Urban, PhD
Robert is Global Head of Johnson & Johnson Innovation. He joined the Johnson & Johnson Family of Companies from the Massachusetts Institute of Technology, where he was the founding Executive Director of the Koch Institute for Integrative Cancer Research. In this leadership role, Robert worked to build the Koch Institute into new standard for interdisciplinary disease-focused research via an expanding, highly-effective, relationship network with other academic oncology centers, industrial partners, cancer-focused philanthropists and investors. During Robert’s tenure, the Koch Institute launched seventeen start-up companies and its technology was the source of over 50 out-licensing transactions. Robert was recruited to MIT from Acretia Inc. – a product acquisition and out-licensing company where he was the President and CEO. During his time at Acretia Inc. the organization conducted technical due diligence on more than 280 product opportunities and completed the acquisition of three distinct product lines. Prior to this, Robert held a variety of business development and clinical development roles in the pharmaceutical industry. He has worked in the areas of oncology, HPV, anti-inflammatory and infectious diseases. His experience includes clinical product development, operations oversight, licensing and acquisitions, capital fund raising, company creation, and building relationships with key thought-leaders. Robert received his Bachelor of Arts degree in Microbiology and his PhD in Microbiology and Immunology from the University of Texas system, and was an Irvington Fellow in structural immunology at Harvard University.